Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top

Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response

or
Journals by subject

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio. 

Register today!

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Most read journal articles

Romosozumab for the treatment of osteoporosis

An Update on Emerging Regenerative Medicine Applications: The Use of Extracellular Vesicles and Exosomes for the Management of Chronic Pain

  • Osteoarthrosis
  • Alternative Treatments for Pain Medicine (C Robinson, Section Editor)

Deprescribing strategies in older patients with heart failure

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study

Nationwide database study of postoperative sequelae and in-hospital mortality in super-elderly hip fracture patients

Four cases of ICI-related fulminant myocarditis

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer. 

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe. 

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area. 

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.
BMC Cancer
Published in:

Open Access 01-12-2024 | Research

Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response

Authors: Faruk Recep Özalp, Kutsal Yörükoğlu, Eda Çalışkan Yıldırım, Mehmet Uzun, Hüseyin Salih Semiz

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Renal cell carcinoma (RCC) is characterised by its immunogenic and proangiogenic nature and its resistance to conventional therapies. The advent of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) has significantly improved patient survival, but resistance to these treatments remains a challenge. B7-H3, a potential immune checkpoint, has been implicated in modulating the tumour microenvironment and immune escape mechanisms in RCC.

Methods

Immunohistochemical analysis of B7-H3 expression was performed in 84 metastatic RCC patients. Tissue microarrays and separate sections of formalin-fixed paraffin-embedded tissue were used for immunohistochemical staining. Membranous staining of the tumor cells was scored and statistical analyses were performed to assess the correlation between B7-H3 expression and treatment outcome.

Results

B7-H3 expression was absent in 31% of patients, while 33.3% had a score of 1+, 31% had 2+, and 4.8% had 3+. High B7-H3 expression correlated with poorer OS (20 months vs. 45 months, p = 0.012). In patients receiving nivolumab, those with high B7-H3 expression had shorter PFS (2 months vs. 8 months, p = 0.037) and OS (17 months vs. 51 months, p = 0.01). B7-H3 expression was the only factor significantly affecting PFS and OS in multivariate analysis.

Conclusion

High B7-H3 expression is associated with poorer survival outcomes and reduced response to nivolumab in metastatic RCC patients. B7-H3 may serve as a predictive biomarker for immunotherapy response. Future studies should explore targeting B7-H3 in combination with existing therapies to enhance treatment efficacy.
Literature
1.
Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.CrossRefPubMed
2.
3.
Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, Vano YA. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 2020;3(3):454–471.
4.
Martin SD, Bhuiyan I, Soleimani M, Wang G. Biomarkers for immune checkpoint inhibitors in renal cell carcinoma. J Clin Med. 2023;12(15).
5.
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.CrossRefPubMedPubMedCentral
6.
Hong S, Yuan Q, Xia H, Dou Y, Sun T, Xie T, et al. Establishment of an ex vivo tissue culture model for evaluation of antitumor efficacy in clear cell renal cell carcinoma. Front Oncol. 2022;12:851191.CrossRefPubMedPubMedCentral
7.
Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD et al. Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines. 2023;11(4).
8.
Seeber A, Klinglmair G, Fritz J, Steinkohl F, Zimmer K-C, Aigner F, et al. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci. 2018;109(5):1583–91.CrossRefPubMedPubMedCentral
9.
Lin C-C, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, et al. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Oncoimmunology. 2024;13(1):2290787.CrossRefPubMed
10.
Jacob S, Daud A. Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. JCO. 2023;41(16suppl):TPS9595–9595.CrossRef
11.
Luo L, Zhu G, Xu H, Yao S, Zhou G, Zhu Y, et al. B7-H3 promotes pathogenesis of Autoimmune Disease and inflammation by regulating the activity of different T cell subsets. PLoS ONE. 2015;10(6):e0130126.CrossRefPubMedPubMedCentral
12.
Wang L, Fraser CC, Kikly K, Wells AD, Han R, Coyle AJ, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005;35(2):428–38.CrossRefPubMed
13.
Prasad DVR, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500–6.CrossRefPubMed
14.
Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–36.CrossRefPubMed
15.
Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, et al. Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. Oncol Lett. 2019;17(4):4004–10.PubMedPubMedCentral
16.
Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang F, et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):13987–95.PubMedPubMedCentral
17.
Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, et al. B7-H3 negatively modulates CTL-Mediated Cancer Immunity. Clin Cancer Res. 2018;24(11):2653–64.CrossRefPubMed
18.
Zhang X, Fang C, Zhang G, Jiang F, Wang L, Hou J. Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis. Oncotarget. 2017;8(54):93156–67.CrossRefPubMedPubMedCentral
19.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
20.
Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A et al. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J Clin Med. 2018;7(7).
21.
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? Curr Oncol Rep. 2021;23(12):147.CrossRefPubMedPubMedCentral
22.
Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.CrossRefPubMedPubMedCentral
23.
Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74.CrossRefPubMed
24.
Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, et al. Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. Ann Diagn Pathol. 2020;46:151483.CrossRefPubMed
25.
Linehan WM, Srinivasan R, Garcia JA. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol. 2013;40(4):511–20.CrossRefPubMedPubMedCentral
26.
Lichtensztajn DY, Hofer BM, Leppert JT, Brooks JD, Chung BI, Shah SA, et al. Associations of Renal Cell Carcinoma Subtype with patient demographics, comorbidities, and Neighborhood Socioeconomic Status in the California Population. Cancer Epidemiol Biomarkers Prev. 2023;32(2):202–7.CrossRefPubMedPubMedCentral
27.
Mancini M, Righetto M, Baggio G. Gender-related Approach to kidney Cancer Management: moving Forward. Int J Mol Sci. 2020;21(9).
28.
Scelo G, Li P, Chanudet E, Muller DC. Variability of sex disparities in Cancer incidence over 30 years: the striking case of kidney Cancer. Eur Urol Focus. 2018;4(4):586–90.CrossRefPubMed
29.
Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 2022;61(1):22–9.CrossRefPubMed
30.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefPubMedPubMedCentral
31.
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, et al. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncol. 2021;17(35):4861–9.CrossRefPubMed
32.
Verhaart SL, Abu-Ghanem Y, Mulder SF, Oosting S, Van Der Veldt A, Osanto S et al. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clin Genitourin Cancer. 2021;19(3):274.e1-274.e16.
33.
Obinata D, Funakoshi D, Sakurai F, Yoshizawa T, Mochida J, Yamaguchi K, et al. Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. Med (Baltim). 2022;101(32):e29510.CrossRef
34.
Evans ST, Jani Y, Jansen CS, Yildirim A, Kalemoglu E, Bilen MA. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther. 2024;25(1):2342599.CrossRefPubMedPubMedCentral
35.
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150–7.CrossRefPubMedPubMedCentral
36.
Li M, Zhang G, Zhang X, Lv G, Wei X, Yuan H, et al. Overexpression of B7-H3 in CD14 + monocytes is associated with renal cell carcinoma progression. Med Oncol. 2014;31(12):349.CrossRefPubMed
37.
Lee JH, Kim YJ, Ryu HW, Shin SW, Kim EJ, Shin SH, et al. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis. Diagn Pathol. 2023;18(1):36.CrossRefPubMedPubMedCentral
38.
Saeednejad Zanjani L, Vafaei S, Abolhasani M, Fattahi F, Madjd Z. Prognostic value of Talin-1 in renal cell carcinoma and its association with B7-H3. Cancer Biomark. 2022;35(3):269–92.CrossRefPubMed
39.
Inamura K, Amori G, Yuasa T, Yamamoto S, Yonese J, Ishikawa Y. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3 + regulatory T cells in renal cell carcinoma. Cancer Manag Res. 2019;11:7021–30.CrossRefPubMedPubMedCentral
40.
Mischinger J, Fröhlich E, Mannweiler S, Meindl C, Absenger-Novak M, Hutterer GC, et al. Prognostic value of B7-H1, B7-H3 and the stage, size, grade and necrosis (SSIGN) score in metastatic clear cell renal cell carcinoma. Cent Eur J Urol. 2019;72(1):23–31.
41.
Zhang X, Ji J, Zhang G, Fang C, Jiang F, Ma S, et al. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma. Onco Targets Ther. 2017;10:5417–24.CrossRefPubMedPubMedCentral
42.
Jin H, Zhu M, Zhang D, Liu X, Guo Y, Xia L, et al. B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer. Cancer Sci. 2023;114(11):4225–36.CrossRefPubMedPubMedCentral
43.
Mei J, Cai Y, Zhu H, Jiang Y, Fu Z, Xu J, et al. High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. NPJ Breast Cancer. 2024;10(1):11.CrossRefPubMedPubMedCentral
44.
Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022;10(4).
45.
Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic groups in Contemporary First-line combination therapies for metastatic renal cell carcinoma. Eur Urol. 2023;84(1):109–16.CrossRefPubMed
Metadata
Title
Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response
Authors
Faruk Recep Özalp
Kutsal Yörükoğlu
Eda Çalışkan Yıldırım
Mehmet Uzun
Hüseyin Salih Semiz
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-13238-x

Other articles of this Issue 1/2024

Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)

Physician-brief advice for promoting smoking cessation among cancer patients on treatment in low and middle-income countries: a scoping review

  • Open Access
  • Original Research

A preliminary study on the reference intervals of serum tumor marker in apparently healthy elderly population in southwestern China using real-world data

Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status

Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer

Carbon-ion radiotherapy alone vs. standard dose photon radiation with carbon-ion radiotherapy boost for high-grade gliomas: a retrospective study

  • Open Access
  • Glioma
  • Original Research
Image Credits